Collegium Pharmaceutical (COLL) Operating Income Growth (1y) (2015 - 2026)
Powered by 
Analysis
Collegium Pharmaceutical (COLL) Operating Income Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 7.43% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 31.43% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -111.70% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -2.34% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -15.58% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -27.06% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 31.60% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -9.25% |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn | -89.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -89.47% |
| Mar 31, 2026 | 42.46% |
| Dec 31, 2025 | 59.42% |
| Sep 30, 2025 | 78.21% |
| Jun 30, 2025 | -26.05% |
| Mar 31, 2025 | -56.16% |
| Dec 31, 2024 | -38.22% |
| Sep 30, 2024 | -22.60% |
| Jun 30, 2024 | 33.22% |
| Mar 31, 2024 | 100.89% |
| Dec 31, 2023 | 424.69% |
| Sep 30, 2023 | 119.93% |
| Jun 30, 2023 | 220.73% |
| Mar 31, 2023 | 345.90% |
| Dec 31, 2022 | 134.46% |
| Sep 30, 2022 | 44.65% |
| Jun 30, 2022 | -32.29% |
| Mar 31, 2022 | -147.26% |
| Dec 31, 2021 | -327.54% |
| Sep 30, 2021 | -27.91% |